



### Suggested Formula

---

#### Hydroquinone 4%, Tretinoin 0.05%, Ascorbic Acid 1.7% in Mometasone Cream 0.1%

Version number: 1.0

Volume: 30 g

---

Hydroquinone, USP (HY113)	1.2 gm
Tretinoin Cream 0.05%	20 gm <sup>1</sup> <u>OR</u>
Tretinoin, USP (R1022)	0.01 gm <sup>2</sup>
Ascorbic Acid, USP (tablet or powder)	0.5 gm (500mg)
Glycerin, USP (G1016)	4 mL
Mometasone Cream 0.1%	QS 30gm

---

#### SUGGESTED COMPOUNDING PROCEDURES

1. Calculate the required quantity of each ingredient for the total amount to be prepared
2. Crush Ascorbic acid tablet or triturate bulk ingredient to fine powder
3. Add Hydroquinone and triturate to mix
4. Add glycerin and triturate to form paste
5. Add Tretinoin Cream by geometric dilution and mix thoroughly
6. Add Mometasone Cream by geometric dilution and mix thoroughly
7. Suggested Quality Assurance
  - a. Appearance
  - b. No visual particulate
  - c. Label - auxiliary labels, storage, BUD, compounded medication

<sup>1</sup>If using Tretinoin bulk powder add to step 3 and then add Glycerin followed by Mometasone Cream.

<sup>2</sup>See precautions below for handling hazardous drugs.

Store at controlled room temperature.

No claims are made as to the safety or efficacy of this preparation. This formulation is provided solely at the unsolicited request of the pharmacist.

Beyond-Use Dates of preparations are conservative estimates by the formulator using reference books, peer-reviewed literature, and intended duration of therapy, formulation from commercially available products, organoleptic observations and current USP guidelines. Compounders may have stability studies performed by a reputable laboratory if they wish to extend the Beyond-Use Date.

A beyond use date should be assigned according to the current USP <795> Guidelines

Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate protective equipment. Use safety enclosures (hoods) when weighing and mixing.

**Hazardous drugs** should be handled according to USP <800>, NIOSH standards and pharmacy SOPs. This preparation should be compounded in a vented or double-HEPA filtered powder containment hood, biological safety cabinet or compounding aseptic containment isolator. Precautions should be taken to prevent cross-contamination and exposure of ingredients to the compounder and contamination of the preparation by the compounder. Wear appropriate personal protective equipment.

Although much attention has been paid to ensure the accuracy of the formulation contained here, Spectrum Pharmacy Products accepts no liability for the loss or damage arising from reliance on the information. Compounding pharmacists using this formula take full responsibility for the formulations and hold Spectrum Pharmacy Products and Spectrum Chemical Mfg Corp. and its officers, directors and employees harmless for any claim arising from use of or reliance on information contained therein.

8/18 rd